Clinical trials: Healthy, Postmenopausal Women
Postmenopause
Study Comparing Premarin®/MPA, PREMPRO® and Provera® in Healthy Postmenopausal Women
The purpose of the study is to evaluate the safety and efficacy of new tablet formulations of Premarin®/medroxyprogesterone (MPA).
- Trial name
- NCT00543634
- Testing
- Premarin/MPA, Provera 10 mg
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Osteopenia
An Ascending Multiple Dose Study Evaluating AMG 167 in Healthy Men and Postmenopausal Women With Low Bone Mineral Density
The purpose of this study is to assess the safety, tolerability, and potential immune response of AMG 167 following multiple subcutaneous (SC, injection under the skin) dose administrations in healthy men and postmenopausal women…
- Trial name
- NCT01101048
- Testing
- AMG 167
- Volunteers
- 74 people
- Sponsor
- Amgen
Calcium Deficiency, Vitamin D Deficiency
Human Pharmacology Trial of Calcium-vitamin D3 Tablet in Healthy Participants
The purpose of this study is to demonstrate that the intestinal absorption of calcium from a newly developed calcium carbonate-vitamin D3 chewable tablet formulation increases the amount of calcium excreted in urine and decreases…
- Trial name
- Osteopro (NCT01639222)
- Testing
- Calcium 500 mg and Vitamin D3 800 IU, Low calcium meals
- Where
- Germany
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Takeda
Anemia
Study of ACE-536 in Healthy Postmenopausal Women
The purpose of this study is to find out whether ACE-536 can be safely given to patients. This study will also look to see if ACE-536 increases red blood cells, the cells that carry oxygen in the body.
- Trial name
- NCT01432717
- Testing
- ACE-536
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Postmenopausal Osteoporosis
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effect of PTH134 at Increasing Doses in Healthy Postmenopausal Subjects
This study is designed to investigate the safety and tolerability of PTH134 in healthy subjects and to assess the exposure from PTH134.
- Trial name
- NCT00676312
- Testing
- PTH134
- Where
- Switzerland
- Volunteers
- 32 people
- Sponsor
- Novartis
Epilepsy
Study of Excretion Balance and Pharmacokinetics of [14C]-Sodium Valproate (3.7 MBq) in Healthy Postmenopausal or Permanently Sterile Female Subjects
Primary Objectives: To determine the excretion balance and systemic exposure of radioactivity after oral administration of [14C]-sodium valproate (VPA) .
- Trial name
- NCT03681158
- Testing
- sodium valproate
- Where
- United Kingdom
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Sanofi
Healthy Postmenopausal Women
A Bioavailability Study of GS1-144 Tablets in Healthy Postmenopausal Women
To evaluate the pharmacokinetic (PK) characteristics of GS1-144 tablets and the relative bioavailability of the two preparations in healthy postmenopausal female subjects in China.
- Trial name
- NCT06983925
- Testing
- GS1-144 Tablet with new preparation (T), GS1-144 Tablet with present preparation (R)
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Healthy
A Drug-drug Interaction Study of Oral 1250 mg of Vatalinib Administered Under Fasting and Fed Conditions With a Proton-pump Inhibitor in Healthy Sterile or Postmenopausal Female Volunteers
This study will determine the effect of acidic drugs such as proton-pump inhibitors on the pharmacokinetics of Vatalinib under fasting and fed conditions.
- Trial name
- NCT00426452
- Testing
- Vatalinib
- Volunteers
- 24 people
- Sponsor
- Novartis
Musculoskeletal Diseases
Phase 1 Study of ACE-083 in Healthy Subjects
This study will evaluate the safety and tolerability of single and multiple doses of ACE-083 as a local injection into selected skeletal muscles of healthy subjects.
- Trial name
- NCT02257489
- Testing
- ACE-083
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Osteoporosis
A Dose Selection Study of Oral Recombinant Salmon Calcitonin (rsCT) in Normal, Healthy, Postmenopausal Women
This study compares the performance of different doses of oral recombinant salmon calcitonin (rsCT).
- Trial name
- NCT00620854
- Testing
- Recombinant Salmon Calcitonin (rsCT), Oral Tablet, Nasal Spray
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Tarsa Therapeutics, Inc.
Postmenopausal Osteoporosis
Effects of Water and Food Intake on the Pharmacokinetics and Pharmacodynamics of Oral Salmon Calcitonin in Healthy Postmenopausal Women
This is a phase I study to analyze the effect of water and food intake on the bioavailability and pharmacodynamic of oral salmon calcitonin (SMC021) and salmon calcitonin nasal spray in post-menopausal women.
- Trial name
- NCT00395395
- Testing
- Oral salmon calcitonin, salmon calcitonin nasal spray
- Where
- Denmark
- Volunteers
- 56 people
- Sponsor
- Novartis
Postmenopause
To Evaluate the Impact of Smoking on PK After Single-dose Oral Administration of GS1-144 Tablets .
A Drug-Drug Interaction Study to Evaluate the Effect of Smoking (CYP1A2 Inducer) on the Pharmacokinetics Following a Single Oral Dose of GS1-144 Tablets in Chinese Healthy Postmenopausal Female Trial Participants
- Trial name
- NCT07534176
- Testing
- GS1-144 tablets
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Breast Cancer
A Study to Assess the Mass Balance of [14C]HRS-8080 in Healthy Chinese Postmenopausal Female Subjects.
This single-part, healthy volunteer study will try to identify how the test medicine is taken up, broken down and removed from the body.
- Trial name
- NCT07320521
- Testing
- [14C]HRS-8080
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Postmenopausal Osteoporosis, Multiple Sites
Safety Study of an Oral Vitamin D Analog in Postmenopausal Women
Determine the safety of 2MD, a vitamin D analog, when administered orally once daily for 28 days in healthy normal postmenopausal women.
- Trial name
- NCT01969656
- Testing
- 2MD, Calcitriol
- Sponsor
- Deltanoid Pharmaceuticals
Prostate Cancer
To Compare the Safety and Pharmacokinetics of PT105 With PT105R in Healthy Postmenopausal Female Volunteers
The purpose of study is to compare the safety and pharmacokinetics of PT105 with PT105R in healthy postmenopausal female volunteers
- Trial name
- NCT04783636
- Testing
- leuprorelin acetate 3.75mg
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Peptron, Inc.
Normal Hepatic Function, Impaired Hepatic Function
Effect of Hepatic Impairment on LDE225..
This study is to evaluate the pharmacokinetics and safety of 800 mg of LDE225 in subjects with impaired hepatic function and healthy subjects with normal hepatic function.
- Trial name
- NCT01764776
- Testing
- LDE225
- Where
- 5 sites in United States, Belgium and 3 more
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Muscular Atrophy
A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 in Healthy Postmenopausal Women
The purpose of this study is to establish safe dose levels of ACE-031 in healthy postmenopausal women following multiple dose administration. This study will also evaluate if ACE-031 has an effect on muscle.
- Trial name
- NCT00952887
- Testing
- ACE-031
- Where
- 2 sites in Canada
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA